EP0805687A4 - Alpha-f toproteine humaine recombinante et ses utilisations - Google Patents
Alpha-f toproteine humaine recombinante et ses utilisationsInfo
- Publication number
- EP0805687A4 EP0805687A4 EP96905219A EP96905219A EP0805687A4 EP 0805687 A4 EP0805687 A4 EP 0805687A4 EP 96905219 A EP96905219 A EP 96905219A EP 96905219 A EP96905219 A EP 96905219A EP 0805687 A4 EP0805687 A4 EP 0805687A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- fetoprotein
- recombinant human
- human alpha
- mammal
- analog
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4715—Pregnancy proteins, e.g. placenta proteins, alpha-feto-protein, pregnancy specific beta glycoprotein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurosurgery (AREA)
- Toxicology (AREA)
- Reproductive Health (AREA)
- Pregnancy & Childbirth (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Gynecology & Obstetrics (AREA)
- Marine Sciences & Fisheries (AREA)
- Pain & Pain Management (AREA)
Abstract
Applications Claiming Priority (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US505012 | 1983-06-16 | ||
US37731195A | 1995-01-24 | 1995-01-24 | |
US37731795A | 1995-01-24 | 1995-01-24 | |
US37731695A | 1995-01-24 | 1995-01-24 | |
US08/377,309 US5965528A (en) | 1991-09-27 | 1995-01-24 | Recombinant human alph-fetoprotein as an immunosuppressive agent |
US377317 | 1995-01-24 | ||
US377309 | 1995-01-24 | ||
US377311 | 1995-01-24 | ||
US377316 | 1995-01-24 | ||
US08/505,012 US6331611B1 (en) | 1991-09-27 | 1995-07-21 | Expression and purification of cloned human alpha-fetoprotein |
PCT/US1996/000996 WO1996022787A1 (fr) | 1995-01-24 | 1996-01-24 | Alpha-f×toproteine humaine recombinante et ses utilisations |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0805687A1 EP0805687A1 (fr) | 1997-11-12 |
EP0805687A4 true EP0805687A4 (fr) | 2000-05-31 |
Family
ID=27541364
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP96905219A Ceased EP0805687A4 (fr) | 1995-01-24 | 1996-01-24 | Alpha-f toproteine humaine recombinante et ses utilisations |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP0805687A4 (fr) |
JP (2) | JPH10513347A (fr) |
CN (1) | CN1150030C (fr) |
AU (1) | AU700975B2 (fr) |
CA (1) | CA2211324C (fr) |
HK (1) | HK1010153A1 (fr) |
WO (1) | WO1996022787A1 (fr) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6288034B1 (en) | 1995-01-24 | 2001-09-11 | Martinex R & D Inc. | Recombinant human alpha-fetoprotein as an immunosuppressive agent |
US5965528A (en) | 1991-09-27 | 1999-10-12 | Mcgill University | Recombinant human alph-fetoprotein as an immunosuppressive agent |
JP3816959B2 (ja) * | 1997-02-13 | 2006-08-30 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 肝細胞癌の予防および処置 |
US7098306B2 (en) | 1997-02-13 | 2006-08-29 | The Regents Of The University Of California | Method and compositions for treating hepatocellular cancer |
US7208576B2 (en) | 1999-01-06 | 2007-04-24 | Merrimack Pharmaceuticals, Inc. | Non-glycosylated human alpha-fetoprotein, methods of production, and uses thereof |
CA2354638C (fr) * | 1999-01-06 | 2013-03-19 | Atlantic Biopharmaceuticals, Inc. | Expression d'alpha-foetoproteines humaines secretees chez des animaux transgeniques |
DE60041189D1 (de) * | 1999-07-12 | 2009-02-05 | Univ Bruxelles | Genetisch modifiziertes nichthumanes tier mit mangel in alpha-fetoprotein |
US7022892B1 (en) | 1999-07-12 | 2006-04-04 | Universite Libre De Bruxelles | Non-human genetically modified mammal lacking the alpha-fetoprotein |
JP3876162B2 (ja) * | 2000-02-10 | 2007-01-31 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 肝細胞癌の治療のための方法及び組成物 |
FI118263B (fi) | 2002-10-09 | 2007-09-14 | Timo Kalevi Korpela | Kaspaasiaktiivisuutta säätelevät peptidit |
US7074561B2 (en) * | 2002-10-22 | 2006-07-11 | Biomerieux, Inc. | Isothermal amplification based assay for the detection and quantitation of alpha-fetoprotein mRNA |
CA2580004A1 (fr) * | 2004-09-09 | 2006-03-23 | Serometrix Llc | Compositions et methodes d'utilisation de peptides inhibiteurs de la croissance de l'alpha-fetoproteine |
US8932829B2 (en) | 2005-07-07 | 2015-01-13 | Elena Dudich | Recombinant alpha-fetoprotein and compositions thereof |
GB0617564D0 (en) * | 2006-09-06 | 2006-10-18 | Ucl Business Plc | Peptides and methods |
EP2111230A4 (fr) * | 2006-12-19 | 2010-11-17 | Merrimack Pharmaceuticals Inc | Coadministration d'alpha-foetoproteine et d'un agent immunomodulateur pour traiter la sclerose en plaques |
WO2008113970A2 (fr) * | 2007-03-16 | 2008-09-25 | Ucl Business Plc | Peptides |
CN105732795A (zh) * | 2016-03-21 | 2016-07-06 | 海南医学院 | 一种获得人类甲胎蛋白的方法 |
CN112898399A (zh) * | 2019-12-03 | 2021-06-04 | 香雪生命科学技术(广东)有限公司 | 源自于afp抗原的短肽 |
CN113416729B (zh) * | 2021-05-18 | 2022-11-22 | 遵义医科大学附属医院 | 一种肝脏靶向调控甲胎蛋白基因的shRNA和cDNA及其应用 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0001812A1 (fr) * | 1977-10-27 | 1979-05-16 | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft | Procédé de préparation et application de la alpha-1-fétoprotéine |
JPH025866A (ja) * | 1988-06-27 | 1990-01-10 | Kansai Shin Gijutsu Kenkyusho:Kk | ヒトアルファフェトプロテインドメインi遺伝子、対応プラスミド組換体、対応形質転換体、該ドメインiの製造法及び製造された該ドメインi |
EP0353814A2 (fr) * | 1988-07-29 | 1990-02-07 | SCLAVO S.p.A. | Peptides synthétiques à activité immunologique, favorisant la production d'anticorps avec haute spécificité contre alpha-fétoprotéine, leur emploi dans le domaine des diagnostiques |
WO1993005774A1 (fr) * | 1991-09-25 | 1993-04-01 | Wisconsin Alumni Research Foundation | Complexes d'antibiotiques d'anthracycline et d'acides gras polyinsatures dans des emulsions de lipides |
US5206153A (en) * | 1990-06-27 | 1993-04-27 | Snow Brand Milk Products Co., Ltd. | Method of producing human α-fetoprotein and product produced thereby |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0356399A3 (fr) * | 1988-08-26 | 1991-03-20 | Sandoz Ag | Dérivés substitués du 4-azatricyclo (22.3.1.04.9) octacos-18-ène, leur préparation et les compositions pharmaceutiques les contenant |
US5342625A (en) * | 1988-09-16 | 1994-08-30 | Sandoz Ltd. | Pharmaceutical compositions comprising cyclosporins |
CA2120131A1 (fr) * | 1991-09-27 | 1994-05-11 | Robert A. Murgita | Expression et purification d'alphafoetoproteine humaine clonee |
US5907649A (en) * | 1994-09-26 | 1999-05-25 | Siemens Aktiengesellschaft | Coupling arrangement for optically coupling together an OEIC module and optical fibers |
-
1996
- 1996-01-24 WO PCT/US1996/000996 patent/WO1996022787A1/fr not_active Application Discontinuation
- 1996-01-24 EP EP96905219A patent/EP0805687A4/fr not_active Ceased
- 1996-01-24 CN CNB96192764XA patent/CN1150030C/zh not_active Expired - Lifetime
- 1996-01-24 AU AU49035/96A patent/AU700975B2/en not_active Expired
- 1996-01-24 JP JP8523001A patent/JPH10513347A/ja active Pending
- 1996-01-24 CA CA2211324A patent/CA2211324C/fr not_active Expired - Lifetime
-
1998
- 1998-10-15 HK HK98111257A patent/HK1010153A1/xx not_active IP Right Cessation
-
2007
- 2007-09-19 JP JP2007243055A patent/JP2008073041A/ja active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0001812A1 (fr) * | 1977-10-27 | 1979-05-16 | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft | Procédé de préparation et application de la alpha-1-fétoprotéine |
JPH025866A (ja) * | 1988-06-27 | 1990-01-10 | Kansai Shin Gijutsu Kenkyusho:Kk | ヒトアルファフェトプロテインドメインi遺伝子、対応プラスミド組換体、対応形質転換体、該ドメインiの製造法及び製造された該ドメインi |
EP0353814A2 (fr) * | 1988-07-29 | 1990-02-07 | SCLAVO S.p.A. | Peptides synthétiques à activité immunologique, favorisant la production d'anticorps avec haute spécificité contre alpha-fétoprotéine, leur emploi dans le domaine des diagnostiques |
US5206153A (en) * | 1990-06-27 | 1993-04-27 | Snow Brand Milk Products Co., Ltd. | Method of producing human α-fetoprotein and product produced thereby |
WO1993005774A1 (fr) * | 1991-09-25 | 1993-04-01 | Wisconsin Alumni Research Foundation | Complexes d'antibiotiques d'anthracycline et d'acides gras polyinsatures dans des emulsions de lipides |
Non-Patent Citations (3)
Title |
---|
BOISMENU R. ET AL.: "Expression of domains of mouse alpha-fetoprotein in Escherichia coli.", LIFE SCIENCES, vol. 43, no. 8, 1988, pages 673 - 681, XP002118047 * |
MURGITA R. ET AL.: "Adult murine T cells activated in vitro by alpha-fetoprotein and naturally occurring T cells in newborn mice: identity in function and cell surface differentiation antigens", PROC. NATL. ACAD. SCI. USA, vol. 75, no. 6, 1978, pages 2897 - 2901, XP002118046 * |
See also references of WO9622787A1 * |
Also Published As
Publication number | Publication date |
---|---|
EP0805687A1 (fr) | 1997-11-12 |
JPH10513347A (ja) | 1998-12-22 |
AU4903596A (en) | 1996-08-14 |
CN1179106A (zh) | 1998-04-15 |
JP2008073041A (ja) | 2008-04-03 |
WO1996022787A1 (fr) | 1996-08-01 |
CA2211324C (fr) | 2012-07-10 |
HK1010153A1 (en) | 1999-06-17 |
CN1150030C (zh) | 2004-05-19 |
AU700975B2 (en) | 1999-01-14 |
CA2211324A1 (fr) | 1996-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0805687A4 (fr) | Alpha-f toproteine humaine recombinante et ses utilisations | |
RO115700B1 (ro) | Metodă de tratament cu interferon | |
IL134345A0 (en) | Methods for treatment of patients afflicted with multiple sclerosis using consensus interferon | |
AP9801392A0 (en) | Concentrated antibody preparation. | |
UA66417C2 (en) | Recombinant adenovirus affecting canines, pharmaceutical composition | |
AU7079396A (en) | Anti-galalpha(1,3)gal antibody binding peptides | |
AU5687896A (en) | Use of alpha 1L-agonists in the treatment of incontinence | |
AU2993297A (en) | Treatment of sickle cell disease, treatment of immune system diseases and other diseases normally associated with sickle cell anemia | |
HK1019856A1 (en) | Therapeutic uses of bpi protein products for human meningococcemia | |
AU4786093A (en) | Non-peptidic surrogates of the ldv sequence and their use in the treatment of inflammation, autoimmune diseases and tumour progression | |
CA2255539A1 (fr) | Utilisations therapeutiques de produits proteiques bpi chez des patients humains souffrant d'une hemorragie causee par un traumatisme | |
AU1209995A (en) | Use of nitric oxide synthase inhibitors in the treatment of autoimmune diseases | |
AU3878895A (en) | Use of nitric oxide donors in medicine | |
AU628288B2 (en) | Cancer-related antigen-specific human immunoglobulins and human/human hybridomas having the ability to produce said human immunoglobulins | |
AU1636492A (en) | Peptides having thrombospondin-like activity and their therapeutic use | |
EP0656069A4 (fr) | Inhibiteurs de la proliferation cellulaire, preparation et utilisation. | |
AU4762893A (en) | Hla-dr3 blocking peptides and their use in the treatment of hla-dr3 associated autoimmune diseases. | |
IL131478A0 (en) | Methods for treatment of scar tissue | |
AU7439996A (en) | Novel uses of mammalian ctla-8 and related reagents | |
IL112993A0 (en) | Recombinant niruses, their preparation and their use in gene therapy | |
WO1995007708A3 (fr) | Utilisation therapeutique d'un produit genique contre la predisposition au retinoblastome | |
MY131599A (en) | Use of il-10 to stimulate peripheral blood mononuclear cell cytolytic activity | |
AUPM598394A0 (en) | Transformed human hepatoma cell line which releases insulin | |
AU7780791A (en) | Neonatal human blood bank and hematopoietic or immune reconstitutions performed therewith | |
AU1592801A (en) | Methods of treating inflammatory bowel disease using cholera toxin B subunit |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT CH DE FR GB IT LI NL SE |
|
17P | Request for examination filed |
Effective date: 19970801 |
|
RIC1 | Information provided on ipc code assigned before grant |
Free format text: 6C 12N 15/12 A, 6C 12N 15/62 B, 6C 07K 14/47 B, 6A 61K 38/17 B, 6C 07K 14/00 B, 6C 12P 21/02 B |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20000414 |
|
AK | Designated contracting states |
Kind code of ref document: A4 Designated state(s): AT CH DE FR GB IT LI NL SE |
|
17Q | First examination report despatched |
Effective date: 20020311 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: MARTINEX R&D INC. |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: MURGITA, ROBERT, A |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED |
|
18R | Application refused |
Effective date: 20040708 |